Meet CarthaGenetics® at the World Orphan Drug Congress

World Orphan Drug Congress has grown to become the largest and most established orphan drugs & rare diseases meeting in Europe and this year will be no exception.

As a leader in Orphans Drugs Early Access Programs in Europe, Including Turkey, CarthaGenetics®, a member of the Swiss Biotech Association and a member of Asebio, is honored to participate in this virtual event, on November 2nd -5th.

If you want to get in touch with our CEO, Philippe Carteron de Balmont, discuss rare disease patient recruitment for your Clinical Trial(s), have information about EAP, please contact him at +41 76 717 37 65 (WhatsApp) or

Share via
Copy link
Powered by Social Snap